583860-52-0

Basic information

• Product Name: 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethanone
• Synonyms: ethanone, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-
• CAS NO: 583860-52-0
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.184
• Mol File: 583860-52-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 374.4°C at 760 mmHg
• Flash Point: 153.5°C
• Density: 1.317g/cm³
• Vapor Pressure: 2.85E-06mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethanone(583860-52-0)
• EPA Substance Registry System: 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethanone(583860-52-0)

Safety Data

• Hazardous Substances Data: 583860-52-0(Hazardous Substances Data)

Usage

General Description

1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethanone is a chemical compound with a molecular formula C10H4O4. It is a derivative of 2,3-dihydro-1,4-benzodioxin and has a hydroxyethanone functional group. 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethanone is commonly used in the synthesis of pharmaceuticals and research chemicals. Its structure and properties make it a versatile building block for the production of various organic compounds. It is also used as a reagent in organic synthesis and chemical research due to its unique structure and reactivity. The chemical is typically handled and stored in a controlled environment due to its potential hazards and should be used by qualified individuals following proper safety protocols.

Upstream product

• 4629-54-3 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone 
• 2879-20-1 1,4-benzodioxan-6-yl methyl ketone 

Downstream Products

• 18212-83-4 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-phenylethanone 

Relevant articles and documents

Structure-activity relationships of triazole-benzodioxine inhibitors of cathepsin X

Cathepsin X is a cysteine carboxypeptidase that is involved in various physiological and pathological processes. In particular, highly elevated expression and activity of cathepsin X has been observed in cancers and neurodegenerative diseases. Previously, we identified compound Z9 (1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((4-isopropyl-4H-1,2,4-triazol-3-yl)thio)ethan-1-one) as a potent and specific reversible cathepsin X inhibitor. Here, we have explored the effects of chemical variations to Z9 of either benzodioxine or triazol moieties, and the importance of the central ketomethylenethio linker. The ketomethylenethio linker was crucial for cathepsin X inhibition, whereas changes of the triazole heterocycle did not alter the inhibitory potencies to a greater extent. Replacement of benzodioxine moiety with substituted benzenes reduced cathepsin X inhibition. Overall, several synthesized compounds showed similar or improved inhibitory potencies against cathepsin X compared to Z9, with IC50 values of 7.1 μM–13.6 μM. Additionally, 25 inhibited prostate cancer cell migration by 21%, which is under the control of cathepsin X.